I'm not sure they are as convenient to treat as treatment-naïve.
When GILD’s phase-3 HCV trials were designed, it wasn’t yet known whether IL28B status would have a bearing on SVR rates, so it made sense to define an interferon intolerant subgroup based on IL28B.
However, now that we know IL28B doesn’t matter in all-DAA regimens, the interferon intolerant classification is essentially obsolete as an entry criterion in all-DAA trials. From an investment standpoint, such patient populations can be considered the same as treatment-naïve, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.